Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 7.2 mg (equivalent: rivastigmine, qty 4.5 mg) - capsule, hard - excipient ingredients: colloidal anhydrous silica; iron oxide red; iron oxide yellow; microcrystalline cellulose; magnesium stearate; gelatin; hypromellose; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; ethanol; shellac; strong ammonia solution; sulfuric acid; purified water; industrial methylated spirit; 2-ethoxyethanol; dimeticone; lecithin - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg (equivalent: rivastigmine, qty 3 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; hypromellose; magnesium stearate; titanium dioxide; iron oxide red; iron oxide yellow; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; potassium hydroxide; ammonia; pharmaceutical glaze - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg (equivalent: rivastigmine, qty 1.5 mg) - capsule, hard - excipient ingredients: gelatin; hypromellose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide yellow; microcrystalline cellulose; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; iron oxide red; ethanol absolute; potassium hydroxide; ammonia; pharmaceutical glaze - exelon is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - rivastigmine hydrogen tartrate - oral solution - 2mg/1ml

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: microcrystalline cellulose; stearic acid; gelatin; iron oxide yellow; maize starch; titanium dioxide; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: titanium dioxide; microcrystalline cellulose; gelatin; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 4.8 mg - capsule - excipient ingredients: iron oxide red; microcrystalline cellulose; gelatin; iron oxide yellow; stearic acid; titanium dioxide; maize starch; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: gelatin; iron oxide red; stearic acid; titanium dioxide; microcrystalline cellulose; maize starch; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; purified water; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 9.6 mg - capsule - excipient ingredients: maize starch; microcrystalline cellulose; gelatin; iron oxide red; stearic acid; titanium dioxide; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - rivastigmine hydrogen tartrate, quantity: 2.4 mg - capsule - excipient ingredients: titanium dioxide; stearic acid; iron oxide yellow; maize starch; gelatin; microcrystalline cellulose; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - rivastigmine is indicated for the treatment of patients with mild to moderately severe dementia of the alzheimer's type